Standard Biotools (LAB) Net Cash Flow Growth (3y) (2013 - 2026)
Standard Biotools (LAB) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 132.07 Bn | 129.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 111.38 Bn | 102.16 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.98 Bn | 67.53 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.32 Bn | 44.65 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.91 Bn | 27.80 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 28.83 Bn | 26.55 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 28.10 Bn | 27.52 Bn | - | - |
| 9 | Koninklijke Philips | 24.30 Bn | 21.26 Bn | 2.01 Bn | -47.25% |
| 10 | Standard Biotools | 302.10 Mn | -153.08 Mn | 11.31 Mn | 65.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.08% |
| Dec 31, 2025 | -34.15% |
| Sep 30, 2025 | -27.83% |
| Jun 30, 2025 | -46.25% |
| Mar 31, 2025 | -127.10% |
| Sep 30, 2024 | -14.44% |
| Jun 30, 2024 | 23.16% |
| Mar 31, 2024 | 143.92% |
| Dec 31, 2023 | -89.78% |
| Sep 30, 2023 | -60.74% |
| Jun 30, 2023 | 54.10% |
| Mar 31, 2023 | 36.37% |
| Dec 31, 2022 | 89.93% |
| Sep 30, 2022 | -112.73% |
| Jun 30, 2022 | 46.31% |
| Mar 31, 2022 | 27.12% |
| Sep 30, 2021 | -125.86% |
| Jun 30, 2021 | -157.38% |
| Mar 31, 2021 | -4.54% |
| Dec 31, 2020 | -10.73% |